In patients treated with tebentafusp, a reduction of circulating CD8 T cells, in particular effector memory T cells, expressing the cognate receptor CXCR3 was observed, while an increase in cytotoxic T cells in the tumor microenvironment was measured [7]. Here, CD8A is linked to neoplasm.